Every S-1 that HEALTHLYNKED CORP (HLYK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow HLYK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HLYK filings page.
HealthLynked Corp. is planning a $7,000,000 public offering of up to 1,750,000 shares of common stock, plus 150,000 shares registered for resale by a selling stockholder. The company expects an offering price between $4.00 and $6.00 per share and has applied to list on Nasdaq under the symbol HLYK; the deal will not close if listing is not approved.
At an assumed $5.00 price for 1,400,000 shares, net proceeds are estimated at about $6.16 million, or $7.14 million if the underwriter’s over-allotment is fully exercised. As of March 31, 2026, HealthLynked held cash of $23,973, with a working capital deficit of $6,658,253 and an accumulated deficit of $52,196,869, leading auditors to raise substantial doubt about its ability to continue as a going concern absent this financing and other capital raises.
HealthLynked Corp. is registering $7,000,000 of common stock in a public offering and 150,000 additional shares for resale by a selling stockholder. The primary sale is expected to price between $4.00 and $6.00 per share, with an assumed 1,400,000 shares at $5.00 for illustrative purposes.
The company estimates net proceeds of about $6.16 million (or $7.14 million with full over-allotment), to fund working capital, capital expenditures, research and development, sales and marketing, and repayment of specific debts. A significant portion of related-party convertible debt held by CEO Dr. Michael Dent is assumed to convert into equity for Nasdaq listing purposes.
HealthLynked reports cash of $37,136, a working capital deficit of $5.46 million and an accumulated deficit of $50.54 million as of December 31, 2025, leading to substantial doubt about its ability to continue as a going concern. Management believes proceeds from this offering, if completed, will help address liquidity concerns for at least the next twelve months.
HealthLynked Corp. is conducting a primary offering of up to 1,750,000 shares of common stock for $7,000,000 under an S-1 registration statement. The assumed price range is $4.00–$6.00 per share, with a base offering of 1,400,000 shares plus a 210,000-share over-allotment option.
The company’s stock currently trades on the OTCQB as “HLYK” and the offering is conditioned on approval for listing on Nasdaq; if Nasdaq does not approve the listing, the offering will not close. At a $5.00 midpoint, net proceeds are estimated at $6,160,000, to be used for working capital, capital expenditures, research and development, sales and marketing, and repayment of indebtedness.
As of September 30, 2025, HealthLynked had $10,911 in cash, a $5,201,336 working capital deficit and a $50,768,392 accumulated deficit, creating substantial doubt about its ability to continue as a going concern. The offering, together with the assumed conversion of $4,500,000 of related-party convertible debt into 1,058,824 shares at $4.25 per share, would turn a shareholders’ deficit of $(5,433,415) into pro forma equity of $5,226,585.
Common shares outstanding are expected to rise from 2,881,104 before the offering to 4,281,104 after the base deal, or 4,491,104 if the over-allotment is fully exercised, at the assumed price. New investors will experience immediate dilution; at a $5.00 price, pro forma net tangible book value would be $0.98 per share, implying dilution of $4.02 per share to new purchasers.